Investors might want to bet on Taysha Gene Therapies, Inc. (TSHA) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since ...

Plumas Bancorp (PLBC) came out with quarterly earnings of $1.05 per share, missing the Zacks Consensus Estimate of $1.2 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.50%. A quarter ago, it was expected that this company would post earnings of $1.13 per share when it actually produced earnings of $1.2, delivering a surprise of +6.19%.Over the last four quarters, the company ha ...

Ferrari (RACE) is a Zacks Rank #1 (Strong Buy) that has an D for Value and an A for Growth. A recent earnings beat has this stock in the spotlight. This luxury auto maker will report earnings again at the end of the month and with the economy remaining resilient we might see a boost in sales. If that continues the stock will grow into is rather high valuation.  Let’s learn more about why this stock is the Bull of the Day.Description                                               Ferrari NV is a holding compa ...

The price trend for TIM S.A. Sponsored ADR (TIMB) has been bearish lately and the stock has lost 6.4% over the past week. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Stree ...

BioMarin Pharmaceutical (BMRN) closed the last trading session at $56.62, gaining 3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $96.69 indicates a 70.8% upside potential.The mean estimate comprises 26 short-term price targets with a standard deviation of $14.53. While the lowest estimate of $65.00 indicates a 14.8% increase from the current price level, the most optimistic ana ...

Company Performance - Progressive reported quarterly earnings of $4.88 per share, exceeding the Zacks Consensus Estimate of $4.43 per share, and up from $2.65 per share a year ago, representing an earnings surprise of +10.16% [1] - The company posted revenues of $21.62 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.51%, and an increase from $18.26 billion year-over-year [2] - Over the last four quarters, Progressive has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Future Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and the earnings outlook for the coming quarters [3][4] - The current consensus EPS estimate for the upcoming quarter is $3.67 on revenues of $22.46 billion, and for the current fiscal year, it is $16.84 on revenues of $87.46 billion [7] - The estimate revisions trend for Progressive was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Insurance - Property and Casualty industry, to which Progressive belongs, is currently in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Applied Materials (AMAT) .Applied Materials currently has an average brokerage recommendation ( ...

分组1 - Prologis reported quarterly funds from operations (FFO) of $1.46 per share, exceeding the Zacks Consensus Estimate of $1.41 per share, and up from $1.34 per share a year ago, representing an FFO surprise of +3.55% [1][2] - The company achieved revenues of $2.03 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.35%, compared to $1.85 billion in the same quarter last year [2] - Prologis has outperformed consensus FFO estimates in all four quarters over the past year and has topped revenue estimates twice in the same period [2] 分组2 - The stock has increased approximately 2.8% since the beginning of the year, while the S&P 500 has gained 6.2% [3] - The current consensus FFO estimate for the upcoming quarter is $1.43 on revenues of $2.03 billion, and for the current fiscal year, it is $5.70 on revenues of $8.09 billion [7] - The Zacks Industry Rank indicates that the REIT and Equity Trust - Other sector is currently in the bottom 38% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Viewpoint - Goldman Sachs reported quarterly earnings of $10.91 per share, exceeding the Zacks Consensus Estimate of $9.43 per share, and showing an increase from $8.62 per share a year ago, representing an earnings surprise of +15.69% [1][2] Financial Performance - The company posted revenues of $14.58 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 8.06%, compared to $12.73 billion in revenues a year ago [2] - Over the last four quarters, Goldman Sachs has consistently surpassed consensus EPS estimates [2] Stock Performance - Goldman shares have increased approximately 22.7% since the beginning of the year, significantly outperforming the S&P 500's gain of 6.2% [3] Future Outlook - The company's earnings outlook will be crucial for determining the sustainability of its stock price movement, with current consensus EPS estimates at $10.04 for the coming quarter and $44.16 for the current fiscal year [4][7] - The Zacks Rank for Goldman Sachs is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Financial - Investment Bank industry is currently ranked in the top 21% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]

First Horizon National (FHN) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.36 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +9.76%. A quarter ago, it was expected that this bank holding company would post earnings of $0.4 per share when it actually produced earnings of $0.42, delivering a surprise of +5%.Over the last four quarter ...